A Phase 2b Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis

Brief description of study

The purpose of this study is to see if an experimental drug called MK-3655 helps people with a liver disease called nonalcoholic steatohepatitis (NASH). “Experimental” means MK-3655 has not been approved for commercial use by the US Food and Drug Administration. This study will test MK-3655 against placebo. A placebo looks like a study drug, but it has no active ingredients. This study will test the safety of MK-3655 compared to placebo and how well MK-3655 works and is tolerated compared to the placebo.


Clinical Study Identifier: s20-00337
ClinicalTrials.gov Identifier: NCT04583423
Principal Investigator: Ira M. Jacobson.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.